The impact of lymphovascular space invasion on recurrence and survival rate among women with stage I endometrioid...

Endometrial cancer is the most common gynecologic malignancy in developed countries, with rising incidence worldwide. While early stage disease generally carries a favorable prognosis, recurrence remains a significant clinical concern. Among the histopathological features, lymphovascular space invasion (LVSI) has emerged as a critical prognostic factor, reflecting tumor aggressiveness and potential for metastatic spread. LVSI is associated with increased risk of recurrence, distant metastasis, and reduced survival, even in patients with otherwise low risk disease. Understanding the role of LVSI in endometrial cancer is essential for refining risk stratification, guiding adjuvant therapy decisions, and improving patient outcomes. Our study to evaluate the impact of lymphovascular space invasion (LVSI) on treatment outcomes, recurrence, and survival in patients with stage I endometrioid endometrial cancer.

A retrospective cohort study was conducted at the Hospital Canselor Tuanku Muhriz (HCTM) Gynecologic Oncology Clinic, with ethical approval from Universiti Kebangsaan Malaysia. Patients with stage I endometrial carcinoma, classified according to the International Federation of Gynecology and Obstetrics (FIGO) 2018, and confirmed on hysterectomy specimens were included. Demographic clinicopathological, and treatment data were collected. LVSI was defined as the presence of tumor cells within endothelial lined spaces. Overall survival (OS) was the primary endpoint. Statistical analyses were performed using SPSS version 26, employing chi square, t tests, and Kaplan-Meier estimates, with significance set at p < 0.05.

Of 180 patients, 163 had endometrioid carcinoma; 114 were included in the final analysis (mean age 58 years; 79.8% postmenopausal). LVSI was present in 14.2% of cases and was associated with higher grade and deeper myometrial invasion. Recurrence occurred in 8.5% overall, with 18.8% in LVSI positive and 4.1% in LVSI negative patients. The 2 year disease free survival (DFS) rate was 93.4% (80.8% LVSI positive vs 99% LVSI negative). The 5 year DFS rate was 91.1% (73.4% LVSI positive vs 94% LVSI negative). The OS rate was 97.3% (87.5% LVSI positive vs 99% LVSI negative). Distant metastasis predicted 2 year DFS, whereas LVSI positivity independently predicted reduced 5 year OS. At 5 years, the DFS rate was 91.1% (SE = 0.031), while the OS rate was 97.3% (SE = 0.013). The similarity between DFS and OS reflects the low number of recurrence and death events, indicating favorable prognosis and effective disease control. Median survival was not reached.

LVSI was associated with higher recurrence and poorer survival in patients with Stage I endometrioid endometrial carcinoma, independently predicting 5-year survival, supporting its role in risk stratification and treatment planning.